Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019337 | Hematologic Neoplasms NIH | 0.35 |
| D009369 | Neoplasms, NIH | 0.17 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001909 | Leukemia HPO | 0.27 |
| HP:0002664 | Neoplasm HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
This is a national multicenter prospective observational study led by the GIMEMA. The GIMEMA-ALLIANCE Platform is also an online monitoring system for patients with hematologic malignancies aiming at helping hematologists in the early recognition and timely management of problems of their patients. Based on patient's rating of specific items (i.e. on the presence of clinically relevant problems or problems with adherence to therapy or risk of SARS-CoV-2 infection), the Platform will automatically send alerts to the treating hematologist (and/or appointed members of the local Team). Physicians will be free to make any action they feel appropriate for the best care of their patients.
Description: To prospectively assess HRQOL in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)
Measure: HRQOL in adult patients with hematologic malignancies Time: After 2 years from date of registrationDescription: To prospectively assess symptoms in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)
Measure: Symptoms in adult patients with hematologic malignancies Time: After 2 years from date of registrationDescription: To prospectively assess adherence to therapy in adult patients with hematologic malignancies, overall and by patient subgroups (e.g., by diagnosis of COVID-19)
Measure: Adherence to therapy in adult patients with hematologic malignancies Time: After 2 years from date of registrationDescription: To describe the prevalence of clinically relevant functional limitations (e.g., physical and social) and symptoms (e.g., fatigue, pain and dyspnea) by type of hematologic malignancy and by type of treatment (e.g., standard chemotherapy of oral anticancer therapies)
Measure: Prevalence of clinically relevant functional limitations and symptoms Time: After 2 years from date of registrationDescription: To investigate factors associated with physical and mental health concerns
Measure: Factors associated with physical and mental health concerns Time: After 2 years from date of registrationDescription: To examine the financial and social impact imposed by the COVID-19 pandemic on patient health outcomes
Measure: Financial and social impact imposed by the COVID-19 pandemic on patient health outcomes Time: After 2 years from date of registrationDescription: To examine the limitations in accessing routine medical care services imposed by the COVID-19 pandemic on patient health outcomes
Measure: Limitations in accessing routine medical care services imposed by the COVID-19 pandemic on patient health outcomes Time: After 2 years from date of registrationDescription: To describe clinical strategies adopted by physicians in response to patient-generated alerts, across different clinical scenarios
Measure: Clinical strategies adopted by physicians Time: After 2 years from date of registrationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports